Abstract 2866
Background
In the Netherlands, hospice care is provided in professional-driven hospices and volunteer-driven hospices. To date, insight is lacking whether the care provided in hospices is appropriate to meet the patient’s needs and wishes. The aim is to gain insight into the characteristics of patients admitted in hospices, their needs and wishes and the care they receive.
Methods
A retrospective patient record study of 1200 hospice patients in the Netherlands. Preliminary results are shown for the first 203 patients. Inclusion criteria are deceased, adult patients admitted in hospice in 2017-2018.The following outcomes were included: Patient characteristics: demographics, disease characteristics, multidimensional symptoms, needs and wishes. Care characteristics: measurement instruments and multidimensional care. Descriptive statistisc was used for analyses.
Results
Preliminary results of 203 patients (mean age 74.8 years, 51.8% woman, 84% cancer diagnoses) from 13 hospices show that initiative for admission is mostly taken by the patient or their family (65.7%). Reasons for admission were described as physical symptoms (73.1%), preferred location of dying (16.1%) and social problems (9.7%). Patients were mostly admitted for last-resort (96.4%) and most patients were in the phase of symptom palliation (79.4%). Problems that were most described were delirium (18.6%), decubitus (12.4%) and edema (6.2%). On average, 10.6 interventions were performed in the first 72 hours per patient. Most were within the physical dimension (76.6%) and least in the social dimension (2.3%). Of the 11 different measurement tools identified, a symptom diary (20.7%) and a palliative assessment (17.2%) were most frequent used.
Conclusions
A preliminary overview of hospice patients and the care they receive was presented. The study is work in progress. Additional data and a comparison between organizational structures of hospices will be presented during the congress.
Clinical trial identification
Editorial acknowledgement
R. Koorn, F. van der Baan, E. de Graaf, S. Teunissen.
Legal entity responsible for the study
S.C.C.M. Teunissen.
Funding
ZonMw.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract